LMNGF News and Press, BioVaxys Technology From 02/18/21

BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production Canada NewsWire SIGNIFICANT ADVANCEMENT TOWARDS LAUNCH OF PHASE I OVARIAN CANCER VACCINE TRIAL VANCOUVER, BC , Feb. 18, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) ...

BioVaxys Announces Broadening Of Share Liquidity With DTCC Full Service Eligibility Canada NewsWire VANCOUVER, British Columbia , Feb. 16, 2021 /CNW/ -- BioVaxys Technology Corp. ( CSE: BIOV, FRA:5LB, OTC:LMNGF) ( "BioVaxys" or "Company") is pleased to an...

BioVaxys Announces Appointment of Corporate Advisor Canada NewsWire VANCOUVER, BC , Feb. 12, 2021 /CNW/ -- BioVaxys Technology Corp. ( CSE: BIOV) (FRA: 5LB) ( "BioVaxys" or "the Company") is pleased to announce that is has appointed Shmuel Farhi as Corpor...

Palm Beach, FL – February 10, 2021 – The incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market. Healthcare physicians are looking for alternate therapies, due to the huge burden of cancer cases and the side e...

BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines - USD$900,000 In-Kind Investment by Procare Health into Phase I Clinical Study for BVX-0918A in the EU - Co-Development of Vaccines fo...

FN Media Group Presents USA News Group News Commentary Vancouver, BC – February 8, 2021 – USA News Group – As regulators in differing markets around the world continue to work on plans surrounding Covid-19 that will either open up their markets o...

Vancouver, British Columbia--(Newsfile Corp. - February 5, 2021) - BioVaxys Technology Corp . (CSE: BIOV) (" BioVaxys " or the " Company "), is pleased to announce that it has closed its previously announced non-brokered private placement (the " Private Placement "). Under the Private Placem...

Palm Beach, FL – February 2, 2021 – Recent reports of ongoing testing regarding the length of time that the initially approved vaccines for COVID-19 will give the patients for immunity after having been inoculated with the vaccine.  Early in the covid-19 pandemic it was u...

BioVaxys SARS-CoV-2 Vaccine Candidate BVX-0320 Stimulates Neutralizing Antibodies To Live COVID-19 Virus PR Newswire VANCOUVER, British Columbia , Feb. 2, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ( "BioVaxys" or ...

Vancouver, BC – February 2, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) (“BioVaxys” or “Company”) is pleased to announce that its Covid-19 vaccine candidate, BVX-0320, elicits a neutralizing antibody response against SARS-...